Casey Tak, Paige Thompson, Jessica L. Morse, Meaghan McCallum
{"title":"Health care resource utilization and health care costs among digital weight-loss intervention participants and nonparticipants","authors":"Casey Tak, Paige Thompson, Jessica L. Morse, Meaghan McCallum","doi":"10.1002/oby.24337","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>The objective of this study was to compare health care resource utilization (HRU), health care costs, and glucagon-like peptide-1 (GLP-1) agonist use among working US adults who engaged in Noom Weight, a smartphone-based lifestyle intervention for weight management, to individuals offered Noom who did not enroll.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Insurance claims data were used to conduct retrospective analyses of 723 Noom participants matched via propensity scores and compared to 723 non-Noom participants at 6 months post index.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Compared to nonparticipants, Noom participants had significantly lower HRU, medical and pharmacy costs, and GLP-1 agonist use in the 6-month post-index period. On average, Noom participants had 3.2 fewer outpatient visits, 0.34 fewer emergency department visits, 0.25 fewer inpatient visits, and 0.012 fewer surgeries than non-Noom participants (all <i>p</i> values <0.001). Noom participants’ health care costs were $831 lower than non-Noom participants. Relative to non-Noom users, Noom participants also had 42% fewer claims for GLP-1 agonists (<i>p</i> = 0.02).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Compared to matched nonparticipants, Noom participation was associated with lower HRU, health care costs, and GLP-1 agonist use at 6 months post index. Results of this study support Noom as a cost-effective and HRU-lowering digital weight-management program for working adults in the United States.</p>\n </section>\n </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 9","pages":"1637-1644"},"PeriodicalIF":4.7000,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24337","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/oby.24337","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
The objective of this study was to compare health care resource utilization (HRU), health care costs, and glucagon-like peptide-1 (GLP-1) agonist use among working US adults who engaged in Noom Weight, a smartphone-based lifestyle intervention for weight management, to individuals offered Noom who did not enroll.
Methods
Insurance claims data were used to conduct retrospective analyses of 723 Noom participants matched via propensity scores and compared to 723 non-Noom participants at 6 months post index.
Results
Compared to nonparticipants, Noom participants had significantly lower HRU, medical and pharmacy costs, and GLP-1 agonist use in the 6-month post-index period. On average, Noom participants had 3.2 fewer outpatient visits, 0.34 fewer emergency department visits, 0.25 fewer inpatient visits, and 0.012 fewer surgeries than non-Noom participants (all p values <0.001). Noom participants’ health care costs were $831 lower than non-Noom participants. Relative to non-Noom users, Noom participants also had 42% fewer claims for GLP-1 agonists (p = 0.02).
Conclusions
Compared to matched nonparticipants, Noom participation was associated with lower HRU, health care costs, and GLP-1 agonist use at 6 months post index. Results of this study support Noom as a cost-effective and HRU-lowering digital weight-management program for working adults in the United States.
期刊介绍:
Obesity is the official journal of The Obesity Society and is the premier source of information for increasing knowledge, fostering translational research from basic to population science, and promoting better treatment for people with obesity. Obesity publishes important peer-reviewed research and cutting-edge reviews, commentaries, and public health and medical developments.